Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
A representative of Japan’s pharmacist association on March 12 reiterated his call for the packaging units of expensive drugs to be aligned to actual clinical use, urging the regulator to consider some kind of pricing measures such as price reductions…
To read the full story
Related Article
- Pharmacies Reel from Pricey Drug Waste, Sparking Calls for Packaging Overhaul and Price Penalties
August 27, 2025
- Japan to Survey Drug Waste at Pharmacies amid Rising Concerns Over Disposal Costs
July 11, 2025
- At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
May 19, 2025
- Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19
March 13, 2025
- JPA Calls for Improving Package Units as Pharmacies Suffer with Unsold Stocks of Pricey Meds
December 19, 2024
REGULATORY
- Takaichi Puts Health Security on Crisis Management Investment Agenda
October 6, 2026
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- RMPs to Become Statutory Requirement under PMD Act in May 2027
October 5, 2026
- Japan Panel Calls for Better Infrastructure to Expand RLT Access
October 5, 2026
- Drug Discovery Fund Cleared to Provide Funding to Startups
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…